View upcoming earnings forecasts and in-depth analysis of company forecasts.

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials in a boost for the UK drugmaker’s pipeline. Depemokimab helped ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

The Moderna lawsuits echo similar claims made by GSK when it sued Pfizer and BioNTech for allegedly infringing upon the company’s mRNA patents back in April. At the time, Pfizer voiced ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

FDA accepted GSK's gepotidacin application for uUTI treatment with a PDUFA date set for March 26, 2025. Gepotidacin showed superior efficacy over nitrofurantoin in EAGLE-3 trial with a 58.5% ...

GSK to pay $2.2 billion to settle 93% of Zantac-related lawsuits. GSK targets £38 billion in sales by 2031, but market estimates fall short at £35.7 billion These cases account for 93% of the ...

On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with ...